12 November 2026 - 13 November 2026
75015 Paris, France
16, rue Jean Rey
UIC-P Espaces Congrès
iPSCs : Recent Clinical Insights & Progress
Registration open until 13 Nov 2026
🧬 iPSC-Derived Cell Therapies Symposium
Advancing the Future of Regenerative Medicine 🚀
We are entering an extraordinary era for regenerative medicine — one where iPSC-derived cell therapies hold the potential to transform the treatment of some of the world’s most challenging diseases.
This symposium will bring together a dynamic international community of scientists, clinicians, biotech leaders, manufacturers, regulators, and innovators dedicated to accelerating the development of transformative therapies for patients.
________________________________________________________________________________________________
📖 Program Overview
The development of induced pluripotent stem cell (iPSC)-derived therapies is opening exciting new opportunities to create innovative — and potentially curative — treatments for diseases with limited or no therapeutic options.
As some of the most advanced therapies in modern medicine, these disruptive technologies also bring significant scientific, regulatory, manufacturing, and clinical challenges linked to the complexity of biological products.
This symposium adopts a unique patient-centered approach, starting with the desired clinical outcome and working backward to optimize every stage of development.
________________________________________________________________________________________________
🔄 From “Bedside Back to Bench”
Unlike traditional scientific meetings based on the classic “bench-to-bedside” pathway, this program takes a reverse-development perspective.
We begin with the ultimate goal:
- ✅ Safe therapies
- ✅ Effective clinical outcomes
- ✅ Successful and scalable cell therapy products
Using this framework, the symposium explores how discovery, translational science, manufacturing, regulatory strategy, and clinical development can be aligned to accelerate patient access to next-generation therapies.
________________________________________________________________________________________________
🌟 Why Attend?
- ✨ Discover the latest advances in iPSC-derived therapies
- 🤝 Network with leading international experts and innovators
- 🧠 Gain strategic insights into translational and clinical development
- 🏭 Explore manufacturing, scalability, and regulatory challenges
- 💼 Connect with key stakeholders across academia and industry
________________________________________________________________________________________________
👥 Who Should Attend?
This symposium is designed for academic and industry professionals involved in the development of iPSC-derived cell therapies at all stages, including:
- 🔬 Researchers & Clinicians
- 📋 Regulatory Professionals
- 🏭 Manufacturers & CDMOs
- 🧪 Preclinical & Clinical Trial Experts
- 📊 CROs & Service Providers
- 💡 Investors & Innovators
Join the community shaping the future of regenerative medicine and help turn scientific breakthroughs into life-changing therapies.
KEYNOTE Speakers confirmed
Prof. Dan S. Kaufman
Professor, Department of Medicine
Co-director of **Sanford Stem Cell Institute
**San Diego, USA
Endowed Chair Director,
Cell Therapy Program
Sanford Advanced Therapy Center
Prof. Deepak Srivastava
Professor of Pediatrics and of Biochemistry & Biophysics,
University of California, San Francisco (UCSF) Medical Center, USA
President of Gladstone Institutes
Director of Roddenberry Stem Cell Center at Gladstone
Prof. Jihwan Song
Professor, Department of Biomedical Science,
CHA University,
President of Korean Society for Stem Cell Research
Founder & CEO iPS Bio, Inc., South Korea
Prof. Keiichi Fukuda
Chief Executive Officer
Heartseed Inc., Tokyo, Japan
Representative Director of the Board
Prof. Hongkui Deng
Boya Chair Professor of Cell Biology,
**Peking University Health Science Center
**School of Basic Medical Sciences
Director of Peking University Stem Cell Research Center, China
Dr. Alex NG
Chief Innovation Officer & Co-founder
GC Therapeutics, USA